

Session Title: #236: Advances in Prevention of Major Malignancies

Session Type: Extended Education Session

Date: Friday, June 4

Location: E354b

Time: 1:00 PM - 3:15 PM

- Advances in Prevention of Major Malignancies
Victor G. Vogel, MD
- 5-alpha reductase inhibitors for prostate cancer prevention
Ian Thompson, MD
- Chemoprevention of colorectal cancer
Monica M. Bertagnolli, MD
- SERMs in the Prevention of Breast Cancer
Jack Cuzick, PhD

Session Title: #216: Genetic and Molecular Predictors in Genitourinary Malignancies

Session Type: Clinical Science Symposium

Date: Saturday, June 5

Location: E Hall D2

Time: 8:00 AM - 9:30 AM

- Genetic and Molecular Predictors in Genitourinary Malignancies
Andrew J. Armstrong, MD, ScM
- Genetic and Molecular Predictors in Genitourinary Malignancies
Adam Stuart Kibel, MD
- #4500-Predicting prostate-cancer-specific death: Is it in the cancer?
Gustavo E Ayala
- #4501-Identification of prognostic genomic markers in patients with localized clear cell renal cell carcinoma (ccRCC).
Brian I. Rini
- #4502-Evaluation of the genetic component of early-onset prostate cancer.
Kathleen A. Cooney

- #4503-Susceptibility loci associated with prostate cancer progression and mortality.

David James Gallagher

- Discussion: Emerging evidence for a genetic risk of prostate cancer

Elaine Ostrander, PhD

Session Title: #268: Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Session Type: Special Session

Date: Saturday, June 5

Location: N Hall B1

Time: 9:30 AM - 12:00 PM

- Opening Session with Presidential Address, NCI Director's Address, David A. Karnofsky Memorial Award Lecture, and The ASCO Cancer Foundation Donor Recognition Awards

Daniel D. Von Hoff, MD

Session Title: #46: Evolving Standards of Care in Advanced Renal Cell Carcinoma

Session Type: Education Session

Date: Saturday, June 5

Location: E Hall D1

Time: 1:15 PM - 2:30 PM

- Systemic Therapies in Advanced Renal Cell Cancer: Current Status

Christopher W. Ryan, MD

- Integration of Nephrectomy in Advanced Renal Cell Cancer Management

Eric Jonasch, MD

- Towards Individualizing Therapy in Advanced Renal Cell Cancer

Primo Lara, MD

Session Title: #179: Genitourinary (Nonprostate) Cancer

Session Type: Poster Discussion Session

Date: Saturday, June 5

Location: E450a

Time: 2:00 PM - 6:00 PM

- Genitourinary (Nonprostate) Cancer

Leonard Joseph Appleman, MD, PhD

- Genitourinary (Nonprostate) Cancer

George Phillips, MD, MBBS, MPH

1 #4520-Association of germline genetic markers in *IL8*, *HIF1A*, *VEGFA*, and *VEGFR2* with treatment response to pazopanib in renal cell carcinoma.

Howard A Ball

2 #4521-Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib.

Karel Eechoute

3 #4522-Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients.

Hai T. Tran

4 #4523-A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.

Daniel Yick Chin Heng

5 #4524-The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration.

Toni K. Choueiri

6 #4525-Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

Susan Halabi

7 #4526-Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma.

Katherine Margaret Krajewski

- Discussion: Prediction and prognosis in renal cell carcinoma

Daniel J. George, MD

9 #4528^ - A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC).

Christopher W. Ryan, MD

10 #4529 - Results of a randomized phase II study investigating multi-peptide vaccination with IMA901 in advanced renal cell carcinoma (RCC).

Carsten Reinhardt, MD, PhD

- Discussion: Trial design and drug development in RCC

Ulka N. Vaishampayan, MD

12 #4531 - Results from SWENOTECA V: A population based protocol for seminomatous testicular cancer.

Torggrim Tandstad

13 #4532 - Risk-adapted management of stage I seminoma: Results of the third Spanish Germ Cell Cancer Group Study.

Jorge Aparicio

14 #4533 - Cardiovascular risk in long-term testicular cancer survivors.

Hege Sagstuen Haugnes

15 #4534 - Total treatment burden in stage I seminoma patients.

Eric Leung

16 #4535 - Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study.

Peter W. M. Chung

17 #4536 - Evolution of management of testicular seminoma: Population-based outcomes with decreased utilization of active therapies.

Craig R. Nichols, MD, FACP

18 #4537 - Risk of secondary malignancy in patients with testicular cancer who have received radiation therapy.

Daniel Lewinshtein

19 #4538 - Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy.

Alan Horwich

- Discussion: Germ cell tumors: is radiation under or over-utilized?

Mary Gospodarowicz, MD

20 #4539 - Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC) - Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial.

David I. Quinn, PhD, FRACP, MBBS

21 #4540-First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit.

Joaquim Bellmunt

22 #4541-Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC).

Noah M. Hahn

- Discussion: Is there a role for targeted therapy in advanced urothelial cancer?

Matthew I. Milowsky, MD

23 #4542-Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer.

Lamont J Barlow

24 #4543-Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle-invasive bladder cancer: A prospective randomized trial.

Savino Mauro Di Stasi

- Discussion: New therapies in non-muscle invasive urothelial cancer

Seth P. Lerner, MD

Session Title: #246: Genitourinary (Nonprostate) Cancer

Session Type: Poster Discussion Session

Date: Saturday, June 5

Location: E Hall D2

Time: 5:00 PM - 6:00 PM

- Genitourinary (Nonprostate) Cancer

Leonard Joseph Appleman, MD, PhD

- Genitourinary (Nonprostate) Cancer

George Phillips, MD, MBBS, MPH

1 #4520-Association of germline genetic markers in *IL8*, *HIF1A*, *VEGFA*, and *VEGFR2* with treatment response to pazopanib in renal cell carcinoma.

Howard A Ball

2 #4521-Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib.

Karel Eechoute

3 #4522-Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients.

Hai T. Tran

4 #4523-A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.

Daniel Yick Chin Heng

5 #4524-The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration.

Toni K. Choueiri

6 #4525-Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

Susan Halabi

7 #4526-Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma.

Katherine Margaret Krajewski

- Discussion: Prediction and prognosis in renal cell carcinoma

Daniel J. George, MD

8 #4527-Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure.

Nizar M. Tannir

9 #4528^~A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC).

Christopher W. Ryan, MD

10 #4529-Results of a randomized phase II study investigating multi-peptide vaccination with IMA901 in advanced renal cell carcinoma (RCC).

Carsten Reinhardt, MD, PhD

- Discussion: Trial design and drug development in RCC

Ulka N. Vaishampayan, MD

12 #4531-Results from SWENOTECA V: A population based protocol for seminomatous testicular cancer.

Torgim Tandstad

13 #4532-Risk-adapted management of stage I seminoma: Results of the third Spanish Germ Cell Cancer Group Study.

Jorge Aparicio

14 #4533-Cardiovascular risk in long-term testicular cancer survivors.

Hege Sagstuen Haugnes

15 #4534-Total treatment burden in stage I seminoma patients.

Eric Leung

16 #4535-Prognostic factors for relapse in stage I seminoma managed with surveillance: A validation study.

Peter W. M. Chung

17 #4536-Evolution of management of testicular seminoma: Population-based outcomes with decreased utilization of active therapies.

Craig R. Nichols, MD, FACP

18 #4537-Risk of secondary malignancy in patients with testicular cancer who have received radiation therapy.

Daniel Lewinshtein

19 #4538-Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy.

Alan Horwich

- Discussion: Germ cell tumors: is radiation under or over-utilized?

Mary Gospodarowicz, MD

20 #4539-Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)-Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial.

David I. Quinn, PhD, FRACP, MBBS

21 #4540-First-line treatment with sunitinib monotherapy in patients with advanced urothelial cancer ineligible for cisplatin-based chemotherapy: Pretreatment levels of IL8 and Hounsfield units as predictors of clinical benefit.

Joaquim Bellmunt

22 #4541-Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC).

Noah M. Hahn

- Discussion: Is there a role for targeted therapy in advanced urothelial cancer?

Matthew I. Milowsky, MD

23 #4542-Phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of BCG-refractory non-muscle-invasive bladder cancer.

Lamont J Barlow

24 #4543-Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle-invasive bladder cancer: A prospective randomized trial.

Savino Mauro Di Stasi

- Discussion: New therapies in non-muscle invasive urothelial cancer

Seth P. Lerner, MD

Session Title: #167: Highlights of the Day I including Clinical Trials Participation Awards

Session Type: Highlights of the Day

Date: Sunday, June 6

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day I including Clinical Trials Participation Awards

Everett E. Vokes, MD

- Clinical Trials Participation Awards

Douglas W. Blayney, MD

- Discussion: Lymphoma and Plasma Cell Disorders

Bruce D. Cheson, MD

- Discussion: Lung Cancer - Local/Regional and Adjuvant Therapy

Alan B Sandler, MD

- Discussion: Patient and Survivor Care

Gretchen Genevieve Kimmick, MD

- Discussion: Melanoma/Skin Cancers

F. Stephen Hodi, MD

Session Title: #152: Genitourinary Cancer (Prostate)

Session Type: Oral Abstract Session

Date: Sunday, June 6

Location: E Hall D2

Time: 9:30 AM - 12:30 PM

- Genitourinary Cancer (Prostate)

Evan Y. Yu, MD

- Genitourinary Cancer (Prostate)

Dana E. Rathkopf, MD

- #CRA4504-Intergroup randomized phase III study of androgen deprivation therapy (ADT) + radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633).

Padraig Richard Warde

- #4505-Impact of radiotherapy (RT) combined with androgen deprivation (ADT) versus ADT alone for local control in clinically locally advanced prostate cancer.

Nicolas Mottet

- #4506-Surgical outcomes and implications for cure in active surveillance patients who undergo delayed radical prostatectomy.

Bruce J Trock, PhD, MPH

- Discussion: Early prostate cancer: How much therapy is too much?

Anthony V D'Amico, MD, PhD

- #LBA4507-A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer

Karim Fizazi

- Discussion: The role of RANKL inhibition in preventing skeletal morbidity from castration resistant prostate cancer

Robert E. Coleman, MD, MBBS

- #4508-Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC).

Johann Sebastian De Bono, MD, PhD

- #4509-Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.

Howard I. Scher

- Discussion: Chemotherapy for castration resistant prostate cancer: Looking beyond docetaxel and mitoxantrone

Ian Tannock, MD, PhD

- #4510-A randomized, multicenter, international phase II study of tasquinimod in chemotherapy-naïve patients with metastatic castrate-resistant prostate cancer (CRPC).

Roberto Pili

- #LBA4511-A randomized, double-blind, placebo controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castrate-resistant prostate cancer (mCRPC): Survival results of CALGB 90401.

William Kevin Kelly

- Discussion: Angiogenic targeting in castration resistant prostate cancer

William L. Dahut, MD

Session Title: #143: Plenary Session including Science of Oncology Award and Lecture

Session Type: Plenary Session

Date: Sunday, June 6

Location: N Hall B1

Time: 1:00 PM - 4:00 PM

- Plenary Session including Science of Oncology Award and Lecture

Douglas W. Blayney, MD

- Plenary Session including Science of Oncology Award and Lecture

Daniel F. Hayes, MD

- Plenary Session including Science of Oncology Award and Lecture

Frank McCormick, PhD, FRS

- #LBA1-Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): A Gynecologic Oncology Group study.

Robert A Burger

- Discussion

Elizabeth A. Eisenhauer, MD

- #2-Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

Elisabeth A. Quoix

- #3-Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC).

Yung-Jue Bang

- Discussion

Martin J. Edelman, MD

- #4-A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma.

Steven O'Day, MD

- Discussion: Ipilimumab: The light at the end of the tunnel?

Vernon K Sondak, MD

Session Title: #168: Highlights of the Day II including Partners in Progress Award

Session Type: Highlights of the Day

Date: Monday, June 7

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day II including Partners in Progress Award

Kim Allyson Margolin, MD

- Highlights of the Day II including Partners in Progress Award

Douglas W. Blayney, MD

- Partners in Progress Award Recipient

Ellen V. Sigal, PhD

- Discussion: Genitourinary (Prostate) Cancer

Nicholas J. Vogelzang, MD

- Discussion: Gastrointestinal (Colorectal) Cancer

Howard S. Hochster, MD

- Discussion: Gynecologic Cancer

Claire F. Verschraegen, MD

- Discussion: Myeloma

Jean L. Harousseau, MD

- Discussion: Cancer Prevention/Epidemiology

Scott Michael Lippman, MD

Session Title: #105: Toward Optimizing Outcomes in Early-stage Testicular Cancer: How Little or How Much Therapy?

Session Type: Education Session

Date: Monday, June 7

Location: E354b

Time: 8:00 AM - 9:15 AM

- Management options for early stage seminoma and non-seminoma

Christian K. Kollmannsberger, MD

- Is RPLND still relevant?

David Peter Wood, MD

- Toxicity and survivorship in testicular cancer survivors. Should it modify what I do?

George J. Bosl, MD

Session Title: #139: The Spectrum of Therapeutic Dilemmas in Kidney Cancer: From Early- to Late-stage Disease

Session Type: Clinical Problems in Oncology Session

Date: Monday, June 7

Location: E451a

Time: 8:00 AM - 9:15 AM

- Diagnosis and Management of the Renal Mass

Steven Campbell, MD, PhD

- Management of Non-clear Cell Histology

Przemyslaw Twardowski, MD

- Optimal Management of Toxicities Related to Targeted Agents

Tim Eisen, PhD, FRCP

Session Title: #180: Genitourinary (Prostate) Cancer

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: E450a

Time: 8:00 AM - 12:00 PM

- Genitourinary (Prostate) Cancer

Andrea Lynne Harzstark, MD

- Genitourinary (Prostate) Cancer

Daniel W Lin

1 #4544-A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis.

Nicholas Mitsiades, MD, PhD

2 #4545-Bone scan "flare" in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

Shreya K. Shah

3 #4546-Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.

Aseem Anand

4 #4547-Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC).

Eleni Efstathiou

5 #4548-Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity.

Tomasz M. Beer, MD, FACP

6 #4549-The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized trials.

Emmanuel S. Antonarakis, MD

- Discussion: Biomarkers of response in prostate cancer

Johann Sebastian De Bono, MD, PhD

7 #4550-Predictors of outcome and subgroup results from the integrated analysis of sipuleucel- τ ; trials in metastatic castration-resistant prostate cancer.

Celestia S. Higano, MD

8 #4551-Persistence of immunotherapy survival effects of sipuleucel- τ ; and relationship to postrandomization docetaxel use in phase III studies.

Daniel Peter Petrylak

9 #4552-Correlation between product parameters and overall survival in three trials of sipuleucel- τ ; , an autologous active cellular immunotherapy for the treatment of prostate cancer.

Frances P Stewart

- Discussion: Can we predict who will respond to immunotherapy?

Robert Dreicer, MD

10 #4553-Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).

Paul L. De Souza

11 #4554-Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts).

Daniel Keizman

12 #4555-Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy.

Mark T. Fleming

13 #4556-ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

Mark N. Stein

14 #4557-Association between genetic polymorphisms in *SLCO1B3* gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC).

Mary-Ellen Taplin, MD

- Discussion: Novel therapies and response predictors for CRPC

Celestia S. Higano, MD

15 #4558-Dynamics of bone mineral density during intermittent androgen deprivation for men with biochemical recurrence of prostate cancer.

Evan Y. Yu, MD

16 #4559-Fractures and post-fracture mortality in elderly prostate cancer (PC) patients receiving androgen deprivation therapy (ADT) in the United States.

Karynsa Cetin

17 #4560-The effect of ADT on objective cognitive performance and self-reported cognitive function in men with prostate cancer.

Shireen Marzouk

- Discussion: The impact of ADT on bone and brain

Matthew Raymond Smith, MD, PhD

18 #4561-The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

David G Bostwick

19 #4562-Effect of inflammation on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

Otis W. Brawley

20 #4563-Positive biopsy (bx) rates for prostate cancer (PCA) based on prostate specific antigen (PSA) grouping in a large cancer screening trial: Prostate, lung, colorectal, and ovarian cancer screening trial (PLCO).

Douglas Reding

21 #4564-Cancer genetics-guided discovery of serum biomarker signatures for prostate cancer.

Silke Gillissen

22 #4565-Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer.

E. David Crawford

- Discussion: Risk identification, chemoprevention, surveillance and neoadjuvant therapy in early prostate cancer

Joel B. Nelson, MD

Session Title: #62: Individualizing Therapy for Locally Advanced and Metastatic Urothelial Cancer

Session Type: Education Session

Date: Monday, June 7

Location: S406 (Vista Room)

Time: 9:30 AM - 10:45 AM

- Review of standard and emerging therapies for localized and advanced urothelial cancer

David I. Quinn, PhD, FRACP, MBBS

- Personalizing therapy for urothelial cancer: clinical and molecular biomarkers

Jonathan E. Rosenberg, MD

- How to overcome barriers to the adoption of neoadjuvant therapy for locally advanced urothelial cancer

Ralph deVere White, PhD

Session Title: #47: Evolving Standards of Care in Metastatic Castration-resistant Prostate Cancer

Session Type: Education Session

Date: Monday, June 7

Location: E Arie Crown Theater

Time: 11:30 AM - 12:45 PM

- Phase III trial results and the impact on standard of care and trial design

Michael J. Morris, MD

- Second line treatment after docetaxel

Kim N. Chi, MD, FRCPC

- Bone directed therapy for prostate cancer: present standards and potential new options

Evan Y. Yu, MD

Session Title: #247: Genitourinary (Prostate) Cancer

Session Type: Poster Discussion Session

Date: Monday, June 7

Location: E Hall D2

Time: 12:00 PM - 1:00 PM

- Genitourinary (Prostate) Cancer

Andrea Lynne Harzstark, MD

- Genitourinary (Prostate) Cancer

Daniel W Lin

1 #4544-A gene expression signature associated with sensitivity to the multikinase inhibitor dasatinib: Implications for development of a noninvasive biomarker for personalized therapy based on circulating tumor cell analysis.

Nicholas Mitsiades, MD, PhD

2 #4545-Bone scan "flare" in patients receiving abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC): Analysis of data from a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

Shreya K. Shah

3 #4546-Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.

Aseem Anand

4 #4547-Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC).

Eleni Efstathiou

5 #4548-Effect of ID1 expression change following chemotherapy on chemotherapy sensitivity.

Tomasz M. Beer, MD, FACP

6 #4549-The effect of changes in PSA kinetics on metastasis-free survival (MFS) in patients with PSA-recurrent prostate cancer (PC) treated with nonhormonal agents: Combined analysis of three randomized trials.

Emmanuel S. Antonarakis, MD

- Discussion: Biomarkers of response in prostate cancer

Johann Sebastian De Bono, MD, PhD

7 #4550-Predictors of outcome and subgroup results from the integrated analysis of sipuleucel-Τ trials in metastatic castration-resistant prostate cancer.

Celestia S. Higano, MD

8 #4551-Persistence of immunotherapy survival effects of sipuleucel-Τ and relationship to postrandomization docetaxel use in phase III studies.

Daniel Peter Petrylak

9 #4552-Correlation between product parameters and overall survival in three trials of sipuleucel-Τ;, an autologous active cellular immunotherapy for the treatment of prostate cancer.

Frances P Stewart

- Discussion: Can we predict who will respond to immunotherapy?

Robert Dreicer, MD

10 #4553-Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naïve, metastatic, castrate-resistant prostate cancer (CRPC).

Paul L. De Souza

11 #4554-Phase I/II double-blinded randomized study to determine the tolerability and efficacy of two different doses of lenalidomide (Len) in biochemically relapsed prostate cancer (BRPC) (M0) patients (pts).

Daniel Keizman

12 #4555-Results of a randomized phase II study of mitoxantrone versus mitoxantrone with cetuximab in metastatic castrate-resistant prostate cancer (CRPC) previously treated with docetaxel-based chemotherapy.

Mark T. Fleming

13 #4556-ECOG 5805: A phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC).

Mark N. Stein

14 #4557-Association between genetic polymorphisms in *SLCO1B3* gene and response to ketoconazole (K) in men with castration-resistant prostate cancer (CRPC).

Mary-Ellen Taplin, MD

- Discussion: Novel therapies and response predictors for CRPC

Celestia S. Higano, MD

15 #4558-Dynamics of bone mineral density during intermittent androgen deprivation for men with biochemical recurrence of prostate cancer.

Evan Y. Yu, MD

16 #4559-Fractures and post-fracture mortality in elderly prostate cancer (PC) patients receiving androgen deprivation therapy (ADT) in the United States.

Karynsa Cetin

17 #4560-The effect of ADT on objective cognitive performance and self-reported cognitive function in men with prostate cancer.

Shireen Marzouk

- Discussion: The impact of ADT on bone and brain

Matthew Raymond Smith, MD, PhD

18 #4561-The predictive value of HGPIN and ASAP for the subsequent diagnosis of prostate cancer in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

David G Bostwick

19 #4562-Effect of inflammation on prostate cancer incidence and dutasteride efficacy in the Reduction by Dutasteride of Cancer Events (REDUCE) study.

Otis W. Brawley

20 #4563-Positive biopsy (bx) rates for prostate cancer (PCA) based on prostate specific antigen (PSA) grouping in a large cancer screening trial: Prostate, lung, colorectal, and ovarian cancer screening trial (PLCO).

Douglas Reding

21 #4564-Cancer genetics-guided discovery of serum biomarker signatures for prostate cancer.

Silke Gillissen

22 #4565-Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer.

E. David Crawford

- Discussion: Risk identification, chemoprevention, surveillance and neoadjuvant therapy in early prostate cancer

Joel B. Nelson, MD

Session Title: #201: Genitourinary Cancer

Session Type: General Poster Session

Date: Monday, June 7

Location: S Hall A2

Time: 1:00 PM - 5:00 PM

1A #4566-The impact of neoadjuvant chemotherapy in small cell carcinoma of the bladder: The M. D. Anderson Cancer Center experience.

Siobhan P Lynch

1B #4567-Impact of dose density of adjuvant chemotherapy for locally advanced urothelial cancer.

Tanya B. Dorff

1C #4568-Concentration-depth profiles of mitomycin-C in the human bladder wall after passive diffusion, thermochemotherapy, and electromotive drug administration.

Gioia Leprini

1D #4569-Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced urothelial cancer (UC) age > 70 years (yrs): SWOG 0028.

Derek Raghavan, MD, PhD

1E #4570-The impact of a bladder cancer diagnosis on smoking behavior: An opportunity to improve care.

Jeffrey C Bassett

1F #4571-Evaluation of African American ethnicity and socioeconomic status as prognostic factors for overall survival in bladder cancer.

Fen Jiang

1G #4572-Gene expression profile of advanced squamous and transitional cell carcinoma of the bladder.

Hussein Mustafa Khaled

1H #4573-Phase II study of gemcitabine, cisplatin, and sunitinib in patients with advanced urothelial carcinoma (UC).

Matt D. Galsky

2A #4574-Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05).

Susanne Krege

2B #4575-Validation of a trimodality treatment and selective organ preservation for bladder cancer: Influence of clinical different parameters on the 15-year long-term outcome.

Frens Steffen Krause

2C #4576-Correlation of disease-free survival at 2 to 3 years and 5-year overall survival in patients with muscle-invasive bladder cancer undergoing radical cystectomy.

Guru Sonpavde

2D #4577-Comparison of HER2 amplification in primary tumors and lymph node metastases of urinary bladder cancer.

Achim Fleischmann

2E #4578-Influence of age and socioeconomic status (SES) on testicular cancer (TC) specific mortality: A population-based study of 27,948 patients.

Sophie D. Fossa, MD

2F #4579-Clinical relevance of germ cell cancer cells detected by real time PCR in apheresis products of poor risk patients undergoing high dose chemotherapy.

Andreas Burchert

2G #4580-Management of testicular neoplasms in France and compliance with national guidelines.

Stephane Culine

2H #4581-2-18fluoro-deoxy-d-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residuals: A retrospective validation of the SEMPET trial.

Mark Bachner

3A #4582-Sunitinib in patients with multiply relapsed or cisplatin-refractory germ cell cancer: A CUOG/GTCSG cooperative phase II study.

Christian K. Kollmannsberger, MD

3B #4583-Progression-free survival (PFS) as a new endpoint for designing phase II trials in patients with refractory germ cell tumors (GCT).

Darren Richard Feldman

3C #4584-Impact of delayed orchiectomy (OE) on overall survival (OS) in patients (pts) with metastatic germ cell tumors (mGCT).

Mikhail Fedyanin

3D #4585-Long term outcome in patients with cisplatin-refractory or multiply relapsed germ cell tumors following treatment with gemcitabine and oxaliplatin +/- paclitaxel.

Karin Oechsle

3E #4586-Residual tumor resection in patients with germ cell tumors (GCT): Use of IGCCCG risk group and tumor volume to predict additional vascular procedures.

Christian Winter

3F #4587-Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy (CT) in nonseminomatous germ cell tumors (NSGCT) patients with poor prognosis: A phase II study.

Alexey Tryakin

3G #4588-A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) in combination with sunitinib.

Asim Amin

3H #4589-Subgroup analysis and updated results of the randomized study comparing sorafenib (So) plus interleukin-2 (IL-2) versus So alone as first-line treatment in metastatic renal cell carcinoma (mRCC).

Giuseppe Procopio

4A #4590-A phase II, single-arm study of AS1411 in metastatic renal cell carcinoma (RCC).

Jonathan E. Rosenberg, MD

4B #4591-Interleukin-2 (IL-2) based immunotherapy for the treatment of metastatic renal cell carcinoma (mRCC): An analysis of 422 consecutive patients treated between 1999 and 2008.

Frede Donskov

4C #4592-Use of a nomogram to quantify overall survival (OS) benefit in patients with metastatic renal cell carcinoma (mRCC) receiving bevacizumab (BEV) with interferon (IFN) versus IFN alone.

Pierre Karakiewicz

4D #4593-Use of the UCLA-integrated staging system (UISS) to predict survival after sunitinib treatment for patients with metastatic renal cell carcinoma.

Frederic Pouliot

4E #4594-TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-α).

Sujata Patil

4F #4595-Overall survival (OS) of metastatic renal cell carcinoma (mRCC) patients corrected for crossover using inverse probability of censoring weights (IPCW) and rank preserving structural failure time (RPSFT) models: Two analyses from the RECORD-1 trial.

Pasi Korhonen

4G #4596-Patient preferences for targeted agents in renal cell carcinoma (RCC): A benefit–risk conjoint study.

A. Brett Hauber

4H #4597-Validation of a kinetic analysis of renal cancer regression and growth following treatment with sunitinib and interferon-alfa (IFN-α): Analysis of the pivotal randomized trial.

Julia Wilkerson

5A #4598-Epidemiological trends in renal cell carcinoma (RCC) in the cytokine (CYT) and targeted therapy (TT) eras: A registry analysis of 28,252 patients (pts).

Derek Way-Jun Shek

5B #4599-Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): Subgroup analysis from a phase II randomized discontinuation trial (RDT).

Pankaj Bhargava

5C #4600-Complete remission with TKI in renal cell carcinomas: Experience in 65 patients of the French Kidney Cancer Group.

Laurence Albiges

5D #4601-A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib.

Nasreen A. Ilias-Khan

5E #4602-Risk of congestive heart failure with VEGF-targeted therapy: A systematic review and meta-analysis of clinical trials.

Fabio Augusto Barros Schutz

5F #4603-The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.

Thomas Powles

5G #4604-Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study.

Elizabeth Rosenberg Plimack

5H #4605-Sorafenib (SOR) safety profile in more than 4,600 patients (pts) with renal cell carcinoma (RCC): Assessment at 3-month (mo) intervals using an integrated database of eight company-sponsored studies.

Martin Gore

6A #4606-Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma.

Zita Dubauskas Lim

6B #4607-Presurgical bevacizumab and sunitinib induced changes in primary clear cell renal tumor tissue.

Axel Bex

6C #4608-Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC).

Susanne Osanto, MD, PhD

6D #4609-Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients.

Georges R Azzi

6E #4610-Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC).

Ana M. Molina

6F #4611-An indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory mRCC patients.

Roman Casciano

6G #4612-Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.

Gerald Hans Mickisch

6H #4613-Outcome of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN).

Stephen Lane Richey

7A #4614-Long-term sorafenib (SOR) safety profile in more than 700 patients (pts) with renal-cell carcinoma (RCC) treated for 12 to 42 months (mos).

Thomas E. Hutson

7B #4615-Final results of a dose-finding phase II trial with a triple combination therapy in metastatic renal cell cancer (mRCC): Bevacizumab (B) plus immunotherapy (IT) plus chemotherapy (C) (BIC), antitumor effects, and variations of circulating t-regulatory cells (TREG).

Rodolfo Passalacqua

7C #4616-Risk of primary progressive disease with tyrosine kinase inhibitors sorafenib and sunitinib in patients with renal cell carcinoma: A meta-analysis

Xiao Su

7D #4617-Effect of GSK-3 inhibition in vitro and in vivo on antitumor effect of sorafenib in renal cell carcinoma (RCC).

Hisashi Kawazoe

7E #4618-Detection of circulating tumor cells in patients with renal cell carcinoma compared with a control group.

Thomas Gutsch

7F #4619-Correlation of regulatory T-cell levels and overall survival in metastatic renal cancer patients treated with sunitinib-based therapy.

Eric Tartour

7G #4620-The effect of sunitinib on immune parameters and haemopoetic stem cell markers in patients with untreated clear cell renal cancer.

Simon Chowdhury

7H #4621-Fibroblast growth factor pathway in renal cell carcinoma.

Ilya Tsimafeyeu

8A #4622-Expression of enhancer of zeste homolog 2 in renal cell carcinoma and relationship to downregulation of micro RNA-101.

Toshihiko Sakurai

8B #4623-Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and non-diabetic patients in general clinical practice.

Nicole Marie Agostino

8C #4624-Renal cell carcinoma in octogenarians: Comprehensive analysis using the SEER database.

Nicholas J Hellenthal

8D #4625-Single-fraction radiosurgery for treatment of spinal and cerebral metastases from renal cell carcinoma under systemic tyrosine kinase inhibition.

Michael D. Staehler

8E #4626-Metastatic renal cell carcinoma (mRCC): Relationship between initial non-renal RECIST-target metastases hypoxia, change after 1 month of sunitinib and therapeutic response: An 18f-MISO PET-CT study.

Florent Hugonnet

8F #4627-Pro-BNP for detection of sunitinib-induced cardiac toxicity in patients with renal cell carcinoma.

Manuela Schmidinger

8G #4628-Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor (b-FGF) as predictive factors for sorafenib plus interferon-alfa-2a (IFN) in metastatic renal cell carcinoma (MRCC): Biologic results from the randomized phase II RAPSODY trial.

Sergio Bracarda

8H #4629-Role of VEGF and VEGFR2 single nucleotide polymorphisms (SNPs) in predicting treatment-induced hypertension (HTN) and clinical outcome (CO) in metastatic clear cell RCC (mccRCC) patients (pts) treated with sunitinib.

Jenny J. Kim

9A #4630-Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC).

Andrea J. Bullock

9B #4631-Serum lactate dehydrogenase (LDH) is a predictive biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma (RCC).

Andrew J. Armstrong, MD, ScM

9C #4632-A phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide (TEE) for localized, high-risk, prostate cancer, RTOG 9902.

Howard Mark Sandler

9D #4633-Treatment of intermediate- or high-risk prostate cancer by dose escalation with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT+HDR-B): Early results of a prospective comparative trial.

Benjamin Guix

9E #4634-Phase I/II trial of combined hormonal therapy and hypofractionated accelerated radiotherapy with concomitant intensity-modulated boost for high-risk prostate cancer: Toxicity analysis.

Harvey Quon

9F #4635-Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy.

Daniel Costin Danila

9G #4636-A sensitive exosome-based biosignature for the diagnosis of prostate cancer.

Christine Kuslich

9H #4637-Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial

10A #4638-Fluorodeoxyglucose (FDG) PET as an outcome measure for metastatic prostate cancer.

Michael J. Morris, MD

10B #4639-Association of genetic polymorphisms in ERCC1 gene with PSA response to carboplatin chemotherapy in men with metastatic castration-resistant prostate cancer (CRPC).

Mari Nakabayashi, MD, PhD

10C #4640-Serum-free circulating DNA as a biomarker of prostate cancer diagnosis.

Edna Gordian

10D #4641-Correlation between serum PSA and testosterone (T) kinetics in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0), after local treatment (tx), treated with intermittent androgen deprivation (IAD).

Victoria J. Sinibaldi

10F #4643-Effect of tissue ischemia on prostatic androgen levels.

Michael Christopher Risk

10G #4644-Prognostic value of metastasis pattern for morbidity in prostate cancer measured by quantitative bone scintigraphy.

Martin Hoejgaard, MD

10H #4645-Performance of expressed prostatic secretion assays in prediction of surgical pathology outcomes in patients undergoing radical prostatectomy.

Chris M Whelan

11A #4646-Correlation of epigenetic silencing of *SOCS3* with a subset of prostate cancer with aggressive behavior.

Francesco Pierconti

11B #4647-Prostate cancer metastasis, the non-canonical Wnt pathway and the transcription factor PITX2.

Ian Vela

11F #4648-PCA3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy.

Koji Okihara

11G #4649-Neuroendocrine carcinoma in conjunction with Gleason score 8-10 prostate cancer: Clinical implications for patients treated with radiotherapy.

Daniel J Krauss

11H #4650-Molecular markers that predict for recurrence in men with margin-positive localized prostate cancer.

Po Yee Yip

12A #4651-Use of a pretreatment systems pathology model to predict the likelihood of disease progression in patients treated with primary radiotherapy.

Michael J. Donovan

12B #4652-Expression of EGFR and HER2/neu and absence of activating mutations in patients with castration-resistant prostate cancer.

Carsten Henning Ohlmann

12F #4653-Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial.

Matthew Raymond Smith, MD, PhD

12G #4654-Prostate cancer in men under the age of 50: A comparison of race and outcomes.

Patrick M Parker

12H #4655-Who receives chemotherapy: An analysis of stage IV prostate cancer (PCa) patients in SEER-Medicare.

Michael Grabner

13A #4656-A population based study of cardiovascular (CV) mortality among patients with prostate cancer (PCa) treated with radical external beam radiation therapy (EBRT) with and without adjuvant androgen deprivation therapy (ADT) at a provincial cancer agency.

Julian Oliver Kim

13B #4657-A retrospective analysis of intramural NCI prostate cancer trials: Progress made and insights gleaned.

James L. Gulley, MD, PhD, FACP

13C #4658-Patterns of use of docetaxel in stage IV prostate cancer (PCa) patients in SEER-Medicare.

Eberechukwu Onukwugha

13D #4659-Characteristics of men with abnormal prostate-specific antigen (PSA) who had a biopsy in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

William Gray Hocking, MD

13E #4660-Phase II trial of RAD001 (R) and bicalutamide (B) for castration-resistant prostate cancer (CPRC).

Geoffrey Colin Buckle

13F #4661-A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer patients with associated cytokine changes.

Geoffrey Gibney

13G #4662-A phase II study of pre-operative figitumumab (F) in patients (pts) with localized prostate cancer (PCa).

Kim N. Chi, MD, FRCPC

13H #4663-Modulation of candidate therapy targets in regionally advanced prostate cancer by androgen ablation and docetaxel.

Vassiliki Tzelepi

14A #4664-Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety.

Donald L. Trump

14B #4665-Correlation of dasatinib (DAS) peak levels with interleukin-8 (IL-8) and monocyte chemotactic protein-1 (MCP-1) levels in patients with castration-resistant progressive prostate cancer (CRPC).

Farshid Dayyani

14C #4666-Cetuximab in combination with docetaxel in patients (pts) with metastatic castration resistant (mCRPC) and docetaxel-refractory prostate cancer: A multicenter phase II trial (SAKK 08/07).

Richard Cathomas

14D #4667-Phase I trial of fractionated-dose ¹⁷⁷lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (¹⁷⁷Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).

Scott T. Tagawa

14E #4668-Phase II trial of lapatinib in patients in stage D0 prostate cancer (E5803): Effect of Kras and EGFR status on clinical outcome.

Yu-Hui Chen

14F #4669-Phase I, dose-escalation study of AGS-1C4D4, an anti-PSCA human antibody in castration-resistant prostate cancer (CRPC).

Michael Anthony Carducci

14G #4670-The effect of inhibition of the insulin-like growth factor receptor with nordihydroguaiaretic acid on PSA progression: Results of a phase II study.

Terence W. Friedlander

14H #4671-Median time to progression in chemotherapy (chemo)-naive patients with castration-resistant prostate cancer (CRPC) treated with abiraterone acetate and low-dose prednisone (Pred).

Charles J. Ryan

15A #4672-Durable disease control, safety, and tolerability of abiraterone acetate (AA) in advanced castration-resistant prostate cancer (CRPC).

Diletta Bianchini

15B #4673-Long-term prostate-specific antigen (PSA) control in prostate cancer (PCa) patients switched from leuprolide to degarelix or receiving continuous degarelix treatment.

Neal D. Shore

15C #4674-HE3235, a synthetic adrenal hormone disease-modifying agent, in castrate resistant prostate cancer (CRPC): Results of phase I/II clinical trial.

Robert B. Montgomery

15D #4675-Association of ADT for older men with biochemical recurrence of prostate cancer with obese frailty and falls: A case-control study.

William Dale, MD, PhD

15E #4676-Effect of toremifene on fracture risk in men younger than age 80 on androgen-deprivation therapy.

Michael K Brawer

15F #4677-Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA) +/- strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747.

Emilio Porfiri

15G #4678-Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials.

Sten Nilsson

15H #4679-Analysis of the cost-effectiveness of zoledronic acid for the prevention of skeletal related events in patients with prostate cancer and bone metastases: A comparison across four European countries.

Marc Botteman

16A #4680-Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride (alpharadin) in patients with castration resistant prostate cancer (CRPC) metastatic to bone.

Jorge A. Carrasquillo

16B #4681-Safety results of a phase III trial evaluating ADT+ docetaxel versus ADT alone in hormone-naïve metastatic prostate cancer patients (GETUG-AFU 15/0403).

Igor Latorzeff

16C #4682-Carboplatin plus weekly docetaxel as second-line chemotherapy in docetaxel-resistant and castration-resistant prostate cancer (CRPC).

Christoph W Reuter

16D #4683-Phase II trial of non pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer: A translational study.

Marco Montanari

16E #4684-Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.

Eric Jay Small, MD

16F #4685-Nonmetastatic, high-risk prostate cancer patients with biochemical relapse after local treatment: A prospective, randomized phase III study comparing hormonal therapy +/- docetaxel: An analysis of final safety results.

Stéphane Oudard

16G #4686-Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study.

Saroj Niraula

16H #4687-Efficacy and toxicity of docetaxel in elderly men with castrate-resistant metastatic prostate cancer.

Dale Randall Shepard

17A #4688-A phase I study of combined docetaxel and repeated high activity rhenium-186- HEDP in castration resistant prostate cancer metastatic to bone (the TAXIUM trial).

Joyce M van Dodewaard-de Jong

17B #4689-Final results of a phase I study of CTLA-4 blockade in combination with GM-CSF for metastatic castration resistant prostate cancer (mCRPC).

Andrea Lynne Harzstark, MD

17C #4690-Correcting overall survival (OS) effect for the impact of cross-over via rank preserving structural failure time (RPSFT) model: Case of mRCC RECORD-1 trial of everolimus (EVE).

Emmanuel Zuber

Session Title: #49: Exploiting the Endocrine Axis in Prostate Cancer Therapy: Current Status and Future Directions

Session Type: Education Session

Date: Monday, June 7

Location: E Hall D2

Time: 1:15 PM - 2:30 PM

- Exploiting the endocrine axis in prostate cancer: what are the new targets?

William K. Oh, MD

- Recent advances in endocrine therapy for prostate cancer: new agents, new options

Mary-Ellen Taplin, MD

- Where is endocrine therapy going in the next five years?

Peter Nelson, MD

Session Title: #169: Highlights of the Day III

Session Type: Highlights of the Day

Date: Tuesday, June 8

Location: E Hall D1

Time: 7:30 AM - 9:00 AM

- Highlights of the Day III

Kathy Miller, MD

- Discussion: Breast Cancer - Local/Regional and Adjuvant Therapy

Kathy Miller, MD

- Discussion: Lung Cancer - Metastatic

Charles M. Rudin, MD, PhD

- Discussion: Sarcoma

Gary K. Schwartz, MD

- Discussion: Gastrointestinal (Noncolorectal) Cancer

C. D. Blanke, MD

- Discussion: Head and Neck Cancer

Everett E. Vokes, MD

Session Title: #90: Localized Prostate Cancer: Reducing Mortality and Burden of Therapy

Session Type: Education Session

Date: Tuesday, June 8

Location: E Arie Crown Theater

Time: 8:00 AM - 9:15 AM

- Everything you need to know about prostate cancer screening

Andrew J. Stephenson, MD

- Elevated PSA: Biopsy or Chemoprevention?

David C Miller, MD

- What is "active surveillance" and what is its role in management today?

Laurence Klotz, MD, FRCSC

Session Title: #153: Genitourinary Cancer (Testes, Kidney, and Bladder)

Session Type: Oral Abstract Session

Date: Tuesday, June 8

Location: E Arie Crown Theater

Time: 9:30 AM - 12:30 PM

- Genitourinary Cancer (Testes, Kidney, and Bladder)

Hyung Lae Kim, MD

- Genitourinary Cancer (Testes, Kidney, and Bladder)

Deborah Ann Bradley, MD

- #4512-A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSSG, and Grupo Germinal (EORTC 30974).

Gedske Daugaard

- #4513-Conventional-dose versus high-dose chemotherapy in relapsed or refractory male germ-cell tumors: A retrospective study in 1,594 patients.

Anja Lorch

- Discussion: Treatment intensity and outcome in germ cell tumors

Derek Raghavan, MD, PhD

- #4514-The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC).

David F. McDermott, MD

- #4530-A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study (CWGS).

Uday B. Dandamudi

- #4516-Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial.

Bernard J. Escudier

- Discussion: Metastatic renal cell carcinoma: which way forward?

Dror Michaelson, MD, PhD

- #4517-Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle invasive bladder cancer (MIBC) (BC2001 CRUK/01/004).

Nicholas David James

- #LBA4518-Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: Results of the SOGUG (Spanish Oncology Genitourinary Group) 99/01 study.

Luis G Paz-Ares

- #LBA4519-Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin based chemotherapy (CHT): Phase III results of EORTC study 30986.

Maria De Santis

- Discussion: Is systemic therapy impacting progress in urothelial cancer?

Cora N. Sternberg, MD